This is a news story, published by Yahoo, that relates primarily to DMD news.
For more disease research news, you can click here:
more disease research newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
muscular dystrophy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest protein dystrophin news, DMD patients news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
human dystrophin geneReuters
•80% Informative
Duchenne muscular dystrophy ( DMD ) failed to improve the motion function of patients in a late-stage trial compared with a placebo.
DMD is a genetic muscle wasting disorder in which most patients lack the protein dystrophin.
The therapy also did not show a significant difference compared to placebo in secondary goals of the study.
VR Score
91
Informative language
97
Neutral language
68
Article tone
formal
Language
English
Language complexity
52
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links